Home Public Health Tags

Public Health

Health Policy 101 is a comprehensive guide covering fundamental aspects of U.S. health policy and programs, including Medicare, Medicaid, the Affordable Care Act, employer-sponsored insurance, the uninsured population, health care costs and affordability, women's health issues, and health care politics. The Public Health chapter examines how public health is governed and delivered in the United States. It includes explanations of key public health frameworks, services, capabilities and characteristics, how the public health system works in state, local and territorial governments, and public health funding, workforce, and communication challenges in an era of declining trust.

View the Chapter →

View the Latest: Public Health

Filter

List Grid

151 - 160 of 265 Results

  • Assessing Monkeypox (MPX) Vaccine Eligibility Across the United States

    Issue Brief

    This analysis examines jurisdictional approaches to eligibility for monkeypox (MPX) vaccine. Overall, almost all jurisdictions have, at minimum, adopted the current approach laid out by the CDC. However, there is substantial variation in how eligibility is defined. Additionally, several jurisdictions lack clear criteria or information on who is eligible or where to get vaccinated. This may impact on who gets vaccinated, lead to geographic disparities, and raises potentially equity challenges.

  • What are the Implications of Long COVID for Employment and Health Coverage?

    Policy Watch

    Long COVID has been described as our “next national health disaster” and the “pandemic after the pandemic,” but we know little about how many people are affected, how long it will last for those affected, and how it could change employment and health coverage landscapes. This policy watch reviews what we know and outlines key questions to watch for regarding employment and coverage outcomes. We continue to follow the research on who is most at risk of long COVID and whether there are interventions that can reduce its incidence, length, or severity.

  • Monkeypox Vaccine Roll-out in the U.S. – Are Jurisdictions Requesting All Their Doses?

    Policy Watch

    This analysis examines monkeypox vaccine allocations and jurisdictional requests. It explores jurisdictional request rate (the number of vaccine does requested as a share of the jurisdiction’s allocation from HHS) for JYNNEOS, the preferred vaccine. Overall, while most jurisdictions have requested at least their full supply, some are well below that mark, raising questions about how quickly their at-risk populations can get protected.

  • How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?

    Issue Brief

    This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.

  • KFF’s Kaiser Health News and Gray Television Partner to Examine the Drive Times and Roadblocks for Stroke Victims in Appalachia and the Mississippi Delta

    News Release

    KHN and Gray Television’s InvestigateTV team joined forces to dig into the underlying reasons why strokes are a deadlier threat across most counties in Appalachia and the Mississippi Delta, rural regions that are characterized by high rates of poverty, vulnerable elderly populations, a shortage of medical providers and an epidemic of local hospital closures.

  • Vaccine Monitor: What We’ve Learned

    News Release

    With nearly all states poised to allow anyone at least 16 years old to get a COVID-19 vaccine, this week’s announcement pausing the distribution of the Johnson & Johnson vaccine to investigate a rare side effect is raising questions about whether and how it will affect the public’s eagerness to get vaccinated.

  • KFF COVID-19 Vaccine Monitor: What We’ve Learned

    Poll Finding

    This brief summarizes key findings and themes from the COVID-19 Vaccine Monitor project that is tracking the dynamic nature of the U.S. public’s attitudes and experiences with COVID-19 vaccination, and is based on more than 11,000 interviews conducted since December 2020.